Alector Licenses AL050 to Genentech for $100 Million Upfront

The Tip Desk · October 28, 2026 · 2 min read

The biotech grants Genentech exclusive worldwide rights to its brain-penetrant GCase enzyme replacement therapy while keeping ownership of the ABC platform.

Alector, Inc. (ALEC), a clinical-stage biotechnology company focused on neurodegeneration, granted Genentech exclusive worldwide rights to develop and commercialize AL050, its brain-penetrant engineered GCase enzyme replacement therapy, in a deal that includes a $100 million upfront payment, potential milestone payments of up to $1.17 billion, and tiered royalties on net sales.

Alector said it is retaining ownership of its Alector Brain Carrier (ABC) platform and full rights to apply that technology across its wholly owned pipeline.

“Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

AL050 is an ABC-enabled engineered glucocerebrosidase designed to cross the blood-brain barrier after peripheral dosing. The company has described the candidate as combining an engineered GCase with improved activity and stability, a silenced effector function intended to maximize safety, and tunable ABC technology aimed at brain delivery.

Preclinical work to date, Alector has said, showed increased GCase activity in rodents and non-human primates and reduced toxic substrate accumulation in a rodent GBA disease model, with no apparent hematologic findings. The company has framed AL050 as a potential therapy for Parkinson’s disease and Lewy body dementia associated with GBA loss-of-function mutations, and subsequently for idiopathic Parkinson’s disease and Lewy body dementia.

Before the Genentech license, Alector had been progressing AL050 through preclinical development and had targeted an investigational new drug submission in 2027. The company had also selected AL050 as the lead candidate for its ABC-enabled GCase program in Parkinson’s disease, alongside AL137 for an ABC-enabled anti-amyloid beta antibody in Alzheimer’s disease.

ABC remains a core platform at Alector. The company has described it as a proprietary blood-brain barrier technology intended to deliver antibodies, enzymes, and nucleic acids to the brain, with tunable transferrin-receptor binding designed to balance brain uptake, potency, and safety.

The Genentech arrangement leaves Alector in control of ABC and of its other wholly owned programs, including AL137 and ABC-enabled siRNA candidates, while Genentech takes exclusive worldwide development and commercialization rights to AL050.